Serum IGF-I levels in the diagnosis and monitoring of acromegaly

Pituitary

Volumn 10, Issue 2, 2007, Pages 173-179

  Brooke, A M ^a   Drake, W M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Diagnosis; IGF I

Indexed keywords

ESTROGEN; GLUCOSE; GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; AGE; ARTICLE; CARDIOVASCULAR DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE SEVERITY; ESTROGEN THERAPY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; INSULIN SENSITIVITY; MORTALITY; NORMAL VALUE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RADIOTHERAPY; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ACROMEGALY; DIAGNOSTIC TECHNIQUES, ENDOCRINE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; REFERENCE STANDARDS;

EID: 34249881623     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0036-8     Document Type: Article

References (63)

1. Wright A, Hill D, Lowy C, Fraser T (1970) Mortality in acromegaly. Q J Med 39:1-16
2. Holdaway I, Rajasoorya C, Gamble G, Stewart A (2004) Long-term treatment outcome in acromegaly. J Clin Endocrinol Metab 89(6):2789-2796
3. Kauppinen-Makelin R, Sane T, Reunanen A et al (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
4. Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
5. Giustina A, Barkan A, Casanueva F et al (2000) Criteria for the cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529
6. Walker JL, Crock PA, Behncken SN et al (1998) A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 83(7):2554-2561
7. Drake WM, Parkinson C, Besser GM, Trainer PJ (2001) Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab 12(9):408-413
8. Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171-1177
9. van der Lely A, Hutson R, Trainer P et al (2001) Long term treatment of acromegaly with pegvisomont, a growth hormone receptor antagonist. Lancet 358:1754-1759
10. Ho K, Weissberger A (1994) Characterization of 24 hour growth hormone (GH) secretion in acromegaly: Implications for diagnosis and therapy. Clin Endocrinol 41:75-83
11. Barkan A, Beitins I, Kelch R (1988) Plasma insulin-like growth factor-I/ somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67:69-73
12. Dobrashian R, O'Halloran D, Hunt A, Beardwell C, Shalet S (1993) Relationship between insulin-like growth factor-I levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol 38:589-593
13. Clemmons DR, Van Wyk JJ (1984) Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab 13(1):113-143
14. Clemmons D, Van Wyk J, Ridgway E, Kliman B, Kjellberg R, Underwood L (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301:1138-1142
15. Kim H, Kwon S, Kim S et al (2001) Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Horm Res 56(3-4):117-123
16. de Herder W, van der Lely A, Janssen J, Uitterlinden P, Hofland L, Lamberts S (1995) IGFBP-3 is a poor parameter for assessment of clinical activity in active acromegaly. Clin Endocrinol 43:501-505
17. Clemmons D (2005) Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion. Endocr Dev 9:55-65
18. Dimaraki E, Jaffe C, DeMott-Friberg R, Chandler W, Barkan A (2002) Acromegaly with apparently normal growth hormone secretion: Implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542
19. Peacey S, Toogood A, Veldhuis J, Thorner M, Shalet S (2001) The relationship between 24 hour growth hormone secretion and insulin-like growth factor-I in patients with successfully treated acromegaly: Impact of surgery or radiotherapy. J Clin Endocrinol Metab 86:259-266
20. Rieu M, Girard F, Bricaire H, Binoux M (1982) The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab 55:147-153
21. Daughaday W, Starkey R, Saltman S, Gavin J, Mills-Dunlap B, Heath-Monnig E (1987) Characterisation of serum growth hormone (GH) and insulin-like growth factor-I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab 65:617-623
22. Marzullo P, Di Somma C, Pratt K et al (2001) Usefulness of different biochemical markers of the insulin-like growth factor family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 86(7):3001-3008
23. Consensus Statement (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89(7):3099-3102
24. Feelders R, Bidlingmaier M, Strasburger C et al (2005) Postoperative evaluation of patients with acromegaly: Clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90(12):6480-6489
25. Lamberts S, Uitterlinden P, Schuijff P, Klijn J (1998) Therapy of acromegaly with sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin Endocrinol 29:411-420
26. van den Berg G, Frolich M, Veldhuis JD, Roelfsema F (1994) Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab 79(6):1706-1715
27. Janssen YJH, Doornbos J, Roelfsema F (1999) Changes in muscle volume, strength and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 84:279-284
28. Gullu S, Keles H, Delibasi T, Tonyuku V, Kamel N, Erdogan G (2004) Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 150:465-471
29. Freda P, Post K, Powell J, Wardlaw S (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808-3816 3808-3816
30. Freda P, Nuruzzaman A, Reyes C, Sundeen R, Post K (2004) Significance of 'abnormal' nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89(2):495-500
31. Holly J, Cotterill A, Jemmott R et al (1991) Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF binding protein-I (IGFBP-1) and sex hormone binding globulin in acromegaly. Clin Endocrinol 34:275-280
32. Ayuk J, Clayton R, Holder G, Sheppard M, Stewart P, Bates A (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89(4):1613-1617
33. Bates A, Evans A, Jones P, Clayton R (1995) Assessment of growth hormone status in acromegaly using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol 42:417-423
34. Kaltsas G, Isidori A, Florakis D et al (2001) Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645-1652
35. Melmed S, Casanueva F, Cavagnini F et al (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
36. Bates AS, Van't Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86(5):293-299
37. Ronchi C, Varca V, Giavoli C et al (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90:1377-1382
38. Barreca A, Ciccarelli F, Minuto F, Bruzzi P, Giordano G, Camanni F (1989) Insulin-like growth factor-I and daily growth hormone profile in the assessment of active acromegaly. Acta endocrinol (Kobenhavn) 120:629-635
39. Holdaway I, Rajasoorya R, Gamble G (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
40. Swearingen B, Barker FG II, Katznelson L et al (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419-3426
41. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transphenoidal adenomectomy for acromegaly. Clin Endocrinol 58:86-92
42. Biermasz N, Dekker F, Pereira A et al (2004) Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89(6):2789-2796
43. Colao A, Marzullo P, Ferone D et al (2000) Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
44. Colao A, Cuocolo A, Marzullo P et al (2001) Is the acromegalic cardiomyopathy reversible? Effect of a 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
45. Puder J, Nilavar S, Post K, Freda P (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90(4):1972-1978
46. Drake WM, Coyte D, Camacho-Hubner C et al (1998) Optimizing growth hormone therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 83:3913-3919
47. Span JPT, Pieters G, Sweep C, Hermus A, Smals A (2000) Gender difference in insulin-like growth factor-I response to growth hormone (GH) treatment in GH-deficient adults: Role of sex hormone replacement. J Clin Endocrinol Metab 85(3):1121
48. van Thiel SW, Romijn JA, Pereira AM et al (2005) Effects of DHEA, superimposed on growth hormone substitution, on quality of life and IGF-I in patients with secondary adrenal insufficiency: A randomised, placebo controlled, crossover trial. J Clin Endocrinol Metab 90(6):3295-3303
49. Brooke A, Kalingag L, Miraki-Moud F et al (2006) Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement. Clin Endocrinol 65:673-680
50. Leifke E, Gorenoi V, Wichers C, Von Zur M, Von Buren E, Brabant G (2000) Age related changes of serum sex hormones, insulin-like growth factor-I and sex hormone binding globulin levels in men: Cross-sectional data from a healthy male cohort. Clin Endocrinol 53:689-695
51. Juul A, Main K, Blum W, Lindholm J, Ranke M, Skakkebaek N (1994) The ratio between serum levels of insulin-like growth factor(IGF)-I and the IGF binding proteins (IGFBP-1, -2, and -3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 41:85-93
52. Landin-Wilhelmsen K, Wilhelmsen L, Lapas G et al (1994) Serum insulin-like growth factor-I in a random population sample of men and women related to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentration of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 41:351-357
53. Ho P, Jaffe C, Friberg R, Chandler W, Barkan A (1994) Persistence of rapid growth hormone pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 78:1403-1410
54. Peacey S, Toogood A, Shalet S (1998) Hypothalamic dysfunction in 'cured' acromegaly is treatment modality dependent. J Clin Endocrinol Metab 83:1682-1686
55. Isaksson O, Jansson J, Sjogren K, Ohlsson C (2001) Metabolic functions of liver-derived (endocrine) insulin-like growth factor-I. Horm Res 55(Suppl 1):18-21
56. Rojdmark S, Brismar K (2001) Decreased IGF-I bioavailability after ethanol abuse in alcoholics: Partial resolution after short term abstinence. J Endocrinol Invest 24:476-482
57. Merimee T, Zapf J, Froesch E (1982) Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 55:999-1002
58. Blum W, Ranke M, Kietzmann K, Tonshoff B, Mehls O (1991) Growth hormone resistance and inhibition of somatomedin activity by excess insulin-like growth factor binding protein in uraemia. Paediatr Nephrol 5:539-544
59. Freda P (2003) Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 13:171-184
60. Jones J, Clemmons D (1995) Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34
61. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A (2001) Diagnostic value of the acid-labile subunit in acromegaly: Evaluation in comparison with insulin-like growth factor-I, and IGF binding protein -1, -2, and -3. J Clin Endocrinol Metab 86:1091-1098
62. Minuto F, Resmini E, Boschetti M et al (2004) Assessment of disease activity in acromegaly by means of a single blood sample: Comparison of the 120th minute post glucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol 61(1):138-144
63. Sneppen S, Lange M, Pedersen L et al (2001) Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly. Growth Horm IGF Res 11(6):384-391